Copyright © 2019. Inderes Oy. All rights reserved.
Search
User account

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Log in
Orion
6396 investors follow this company
BUY 43.91 LOWEST 43.40 VOLUME 398 621
SELL 43.94 HIGHEST 44.09 VALUE 17,482 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Analyytikko

Petri Kajaani
+358 50 527 8680

Upcoming events

5
Feb
Tilinpäätöstiedotteet

Latest insider trading

Type: stock_exchange_release
22.1.
2020

ORION CORPORATION  STOCK EXCHANGE RELEASE 22 JANUARY 2020 at 12.45 EET
        

Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion Corporation

Type: stock_exchange_release
22.1.
2020

ORION CORPORATION PRESS RELEASE 22 JANUARY 2019 at 09.00 EET             
         
Orion will publish its Financial Statement Release for 2019 on Wednesday, 5 February 2020 approximately at 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing.

Type: stock_exchange_release
21.1.
2020

ORION CORPORATION STOCK EXCHANGE RELEASE 21 JANUARY 2020 at 9.00 EET             
         
228,223 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 228,223 A shares have been converted into 228,223 B shares. The conversion has been entered into the Trade Register on 21 January 2020.

Type: stock_exchange_release
30.12.
2019

ORION CORPORATION PRESS RELEASE 30 DECEMBER 2019 at 9.00 EET             
         

Orion Corporation (“Orion”) and Lotus Pharmaceutical Co., Ltd. (“Lotus”) have made a marketing and distribution agreement for Orion’s Parkinson’s disease drugs Stalevo® and Comtan® in parts of Asia.

Type: stock_exchange_release
18.12.
2019

ORION CORPORATION STOCK EXCHANGE RELEASE 18 DECEMBER 2019 at 10.15 EET             
         
33,944 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 33,944 A shares have been converted into 33,944 B shares. The conversion has been entered into the Trade Register on 18 December 2019.

Type: stock_exchange_release
13.12.
2019

ORION CORPORATION      MANAGERS’ TRANSACTIONS 13 December 2019 at 15.15 EET

Orion Corporation: Managers’ transactions – Sydäntutkimussäätiö sr.

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Type: stock_exchange_release
9.12.
2019

ORION CORPORATION      MANAGERS’ TRANSACTIONS 9 December 2019 at 10.45 EET

Orion Corporation: Managers’ transactions – Mikael Silvennoinen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Type: stock_exchange_release
9.12.
2019

ORION CORPORATION      MANAGERS’ TRANSACTIONS 09 December 2019 at 10.30 EET

Orion Corporation: Managers’ transactions – Agendum Oy

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Type: stock_exchange_release
9.12.
2019

Orion Corporation                        Press release                               9 December at 10.15 EET

Type: stock_exchange_release
2.12.
2019

Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND

Orion Corporation                        Press release                               2 December 2019 at 1.00 p.m. EET

Orion

Orion lyhyesti

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.